AI assistant
AGRONOMICS LIMITED — Net Asset Value 2013
Apr 9, 2013
7474_rns_2013-04-09_20a4ca4e-107f-47d4-81ef-44e7445b5ec8.html
Net Asset Value
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 8542B
Port Erin Biopharma Investments Ltd
09 April 2013
Port Erin Biopharma Investments Limited ("The Company")
Net Asset Value calculation to 31st March 2013
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 March 2013 was 11.22 pence per share, including un-invested cash of £287,310. The portfolio is valued under IFRS at bid price. This quarter's NAV represents a considerable increase of 18.1% from the previous valuation of 9.50 pence per share, which included un-invested cash of £101,241. The revenue reserve has increased substantially to just over £1.0 million and represents a return of over 37.2% on investments after listing and operating costs."
| Unaudited to 31 March 2013 £ |
||
| Fixed Assets | ||
| Investments | 3,434,606 | |
| Current Assets | ||
| Debtors: amounts owing | 5,690 | |
| Un-invested cash | 287,310 | |
| Current Liabilities | ||
| Creditors: amounts due | (24,000) | |
| 3,703,606 | ||
| Capital and Reserves | ||
| Share Capital | 33 | |
| Share Premium | 2,699,011 | |
| Capital reserve - realised | 0 | |
| Capital reserve - unrealised | 0 | |
| Revenue reserve | 1,004,562 | |
| 3,703,606 | ||
| Shares in Issue | 33,000,000 | |
| Net Asset Value per share | 11.22 pence |
--- ENDS ---
Portfolio Details
| Investments Schedule at 31st March 2013 | Valuation £ | Portfolio % |
| Synergy Pharmaceuticals Inc. | 318,602 | 9.3% |
| Gilead Sciences Inc. | 276,677 | 8.1% |
| Summit Corporation plc | 254,061 | 7.4% |
| Celgene Corporation | 220,975 | 6.4% |
| Arrowhead Research | 146,728 | 4.3% |
| Pfizer Inc. | 140,322 | 4.1% |
| Biogen Idec Inc. | 139,516 | 4.1% |
| TrovaGene Inc. | 122,493 | 3.6% |
| Nektar Therapeutics | 121,507 | 3.5% |
| 1,740,882 | 50.7% | |
| Aggregate value of remaining holdings below 3% of total portfolio | 1,693,724 | 49.3% |
| TOTAL INVESTMENTS | 3,434,606 | 100.0% |
For further information, please contact:
| Port Erin Biopharma Investments Ltd | Libertas Capital Corporate Finance Limited | Peterhouse Capital Limited |
| The Company | Nomad | Broker |
| Denham Eke +44 162 463 9396 |
Sandy Jamieson +44 207 569 9650 |
Jon Levinson +44 207 562 3350 |
This information is provided by RNS
The company news service from the London Stock Exchange
END
NAVQVLFBXZFLBBD